HGBL
ACHAT TOTAL: 90000 titres (~99335 USD)
- Insiders
- COBB BRIAN J., Dove Nicholas Kirk, Hounsell Bruce Kenneth
- Total bought
- $99,335
- Total sold
- —
- Last activity
- 2026-08-20
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-23
HGBL presents a mixed signal: a meaningful insider cluster buy post-Q2 earnings and a strategic acquisition (Boston Note Company) suggest management conviction in the turnaround narrative, but the underlying financial…
The first sentence of the analysis written for HGBL on 2026-08-23 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 27.1% | 31.3% | 35.3% | 22.2% | 42.7% | |
| Ebit Margin | 11.0% | 20.0% | 23.7% | 23.7% | 11.7% | |
| Ebitda Margin | 13.2% | 22.7% | 24.5% | 24.8% | 13.5% | |
| Operating Profit Margin | 11.0% | 20.0% | 23.7% | 23.7% | 11.7% | |
| Pretax Profit Margin | 11.5% | 19.8% | 23.1% | 23.5% | 11.6% | |
| Continuous Operations Profit Margin | 7.0% | 11.4% | 20.6% | 33.0% | 11.8% | |
| Net Profit Margin | 7.0% | 11.4% | 20.6% | 33.0% | 11.8% | |
| Bottom Line Profit Margin | 7.0% | 11.4% | 20.6% | 33.0% | 11.8% | |
| Current Ratio | 2.162 | 2.269 | 1.784 | 1.472 | 1.637 | |
| Quick Ratio | 1.780 | 1.903 | 1.440 | 1.188 | 1.411 | |
| Solvency Ratio | 0.221 | 0.399 | 0.588 | 0.832 | 0.197 | |
| Cash Ratio | 1.321 | 1.490 | 0.833 | 0.781 | 0.958 | |
| Price To Earnings Ratio | 12.400 | 13.214 | 8.176 | 5.465 | 21.719 | |
| Price To Earnings Growth Ratio | -0.434 | -0.225 | -0.391 | 0.014 | -0.297 | |
| Forward Price To Earnings Growth Ratio | -0.434 | -0.225 | -0.391 | 0.014 | -0.297 | |
| Price To Earnings Diluted Ratio | 12.400 | 13.214 | 8.424 | 5.595 | 22.612 | |
| Price To Earnings Diluted Growth Ratio | -0.434 | -0.230 | -0.393 | 0.014 | -0.312 | |
| Price To Book Ratio | 0.645 | 1.050 | 1.669 | 1.752 | 2.032 | |
| Price To Sales Ratio | 0.847 | 1.510 | 1.684 | 1.804 | 2.571 | |
| Price To Free Cash Flow Ratio | -18.515 | 9.001 | 7.988 | 13.504 | -16.348 | |
| Price To Operating Cash Flow Ratio | 7.038 | 8.842 | 7.831 | 13.056 | -25.203 | |
| Debt To Assets Ratio | 0.065 | 0.033 | 0.119 | 0.106 | 0.130 | |
| Debt To Equity Ratio | 0.085 | 0.042 | 0.162 | 0.148 | 0.202 | |
| Debt To Capital Ratio | 0.079 | 0.040 | 0.139 | 0.129 | 0.168 | |
| Long Term Debt To Capital Ratio | 0.058 | 0.000 | 0.083 | 0.018 | 0.040 | |
| Financial Leverage Ratio | 1.320 | 1.247 | 1.362 | 1.399 | 1.546 | |
| Working Capital Turnover Ratio | 2.787 | 3.015 | 6.299 | 5.610 | 2.342 | |
| Operating Cash Flow Ratio | 0.395 | 0.531 | 0.884 | 0.400 | -0.185 | |
| Operating Cash Flow Sales Ratio | 0.120 | 0.171 | 0.215 | 0.138 | -0.102 | |
| Free Cash Flow Operating Cash Flow Ratio | -0.380 | 0.982 | 0.980 | 0.967 | 1.542 | |
| Debt Service Coverage Ratio | 0.000 | 13.367 | 6.472 | 4.581 | 1.413 | |
| Interest Coverage Ratio | 0.000 | 97.484 | 44.194 | 98.407 | 137.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 19.608 | 7.514 | 1.901 | -1.061 | |
| Operating Cash Flow Coverage Ratio | 1.073 | 2.856 | 1.318 | 0.907 | -0.400 | |
| Capital Expenditure Coverage Ratio | 0.725 | 56.533 | 50.665 | 30.153 | -1.846 | |
| Dividend Paid And Capex Coverage Ratio | 0.725 | 56.533 | 50.665 | 30.153 | -1.846 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 4.206 | 4.794 | 6.712 | 6.788 | 17.060 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 27.1% | ▼-4.2% | ▼-4.6% |
| Ebit Margin | 11.0% | ▼-9.0% | ▼-7.0% |
| Ebitda Margin | 13.2% | ▼-9.5% | ▼-6.5% |
| Operating Profit Margin | 11.0% | ▼-9.0% | ▼-7.0% |
| Pretax Profit Margin | 11.5% | ▼-8.3% | ▼-6.4% |
| Continuous Operations Profit Margin | 7.0% | ▼-4.4% | ▼-9.8% |
| Net Profit Margin | 7.0% | ▼-4.4% | ▼-9.8% |
| Bottom Line Profit Margin | 7.0% | ▼-4.4% | ▼-9.8% |
| Current Ratio | 2.162 | ▼-0.107 | ▲0.297 |
| Quick Ratio | 1.780 | ▼-0.122 | ▲0.236 |
| Solvency Ratio | 0.221 | ▼-0.178 | ▼-0.226 |
| Cash Ratio | 1.321 | ▼-0.169 | ▲0.244 |
| Price To Earnings Ratio | 12.400 | ▼-0.814 | ▲0.205 |
| Price To Earnings Growth Ratio | -0.434 | ▼-0.209 | ▼-0.167 |
| Forward Price To Earnings Growth Ratio | -0.434 | ▼-0.209 | ▼-0.167 |
| Price To Earnings Diluted Ratio | 12.400 | ▼-0.814 | ▼-0.049 |
| Price To Earnings Diluted Growth Ratio | -0.434 | ▼-0.204 | ▼-0.163 |
| Price To Book Ratio | 0.645 | ▼-0.405 | ▼-0.785 |
| Price To Sales Ratio | 0.847 | ▼-0.662 | ▼-0.836 |
| Price To Free Cash Flow Ratio | -18.515 | ▼-27.515 | ▼-17.641 |
| Price To Operating Cash Flow Ratio | 7.038 | ▼-1.803 | ▲4.726 |
| Debt To Assets Ratio | 0.065 | ▲0.031 | ▼-0.026 |
| Debt To Equity Ratio | 0.085 | ▲0.044 | ▼-0.042 |
| Debt To Capital Ratio | 0.079 | ▲0.039 | ▼-0.032 |
| Long Term Debt To Capital Ratio | 0.058 | ▲0.058 | ▲0.018 |
| Financial Leverage Ratio | 1.320 | ▲0.073 | ▼-0.054 |
| Working Capital Turnover Ratio | 2.787 | ▼-0.229 | ▼-1.224 |
| Operating Cash Flow Ratio | 0.395 | ▼-0.136 | ▼-0.010 |
| Operating Cash Flow Sales Ratio | 0.120 | ▼-0.050 | ▲0.012 |
| Free Cash Flow Operating Cash Flow Ratio | -0.380 | ▼-1.363 | ▼-1.198 |
| Debt Service Coverage Ratio | 0.000 | ▼-13.367 | ▼-5.167 |
| Interest Coverage Ratio | 0.000 | ▼-97.484 | ▼-75.417 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-19.608 | ▼-5.592 |
| Operating Cash Flow Coverage Ratio | 1.073 | ▼-1.783 | ▼-0.078 |
| Capital Expenditure Coverage Ratio | 0.725 | ▼-55.808 | ▼-26.521 |
| Dividend Paid And Capex Coverage Ratio | 0.725 | ▼-55.808 | ▼-26.521 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 4.206 | ▼-0.588 | ▼-3.706 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $43.2M | $68.5M | $102.0M | $84.6M | $66.3M | |
| Enterprise value | $28.4M | $49.4M | $99.6M | $79.1M | $59.3M | |
| EV / Sales | 0.56x | 1.09x | 1.64x | 1.69x | 2.30x | |
| EV / Op. cash flow | 4.63x | 6.38x | 7.65x | 12.21x | -22.53x | |
| EV / Free cash flow | -12.17x | 6.50x | 7.80x | 12.62x | -14.61x | |
| EV / EBITDA | 4.21x | 4.79x | 6.71x | 6.79x | 17.06x | |
| Net debt / EBITDA | -2.19x | -1.85x | -0.16x | -0.47x | -2.03x | |
| Current ratio | 2.16x | 2.27x | 1.78x | 1.47x | 1.64x | |
| Income quality | 1.71x | 1.50x | 1.04x | 0.42x | -0.86x | |
| Graham number | $2 | $2 | $4 | $4 | $1 | |
| Graham net-net | $0 | $0 | -$0 | -$0 | $0 | |
| Tax burden | 61.4% | 57.8% | 89.1% | 140.8% | 102.0% | |
| Interest burden | 104.6% | 99.0% | 97.7% | 99.0% | 99.3% | |
| Working capital | $18.1M | $18.5M | $11.6M | $7.7M | $9.1M | |
| Invested capital | $41.0M | $33.2M | $27.0M | $23.6M | $25.2M | |
| Return on assets | 4.1% | 6.4% | 15.0% | 22.9% | 6.0% | |
| Operating ROA | 6.6% | 11.0% | 19.0% | 18.8% | 6.3% | |
| Return on tangible assets | 4.6% | 7.4% | 17.3% | 27.7% | 7.9% | |
| Return on equity | 5.4% | 7.9% | 20.4% | 32.1% | 9.4% | |
| Return on invested capital | 4.7% | 7.7% | 18.0% | 20.1% | 7.7% | |
| Return on capital employed | 7.7% | 13.6% | 20.9% | 21.7% | 8.3% | |
| Earnings yield | 8.3% | 7.6% | 12.2% | 18.3% | 4.6% | |
| Free cash flow yield | -5.4% | 11.1% | 12.5% | 7.4% | -6.1% | |
| Capex / Op. cash flow | 138.0% | 1.8% | 2.0% | 3.3% | -54.2% | |
| Capex / Depreciation | 1241.9% | 11.0% | 50.0% | 40.1% | 309.8% | |
| Capex / Sales | 16.6% | 0.3% | 0.4% | 0.5% | 5.5% | |
| SG&A / Sales | 15.2% | 16.5% | 11.7% | 12.2% | 31.2% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.8% | 2.8% | 1.3% | 1.2% | 1.6% | |
| Intangibles / Total assets | 11.9% | 13.3% | 13.5% | 17.2% | 23.8% | |
| Days sales outstanding | 46d | 40d | 12d | 43d | 71d | |
| Days payables outstanding | 71d | 87d | 46d | 32d | 159d | |
| Operating cycle | 104d | 103d | 59d | 89d | 150d | |
| Cash conversion cycle | 33d | 16d | 12d | 57d | -9d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-13 Heritage Global Inc. (HGBL) Q2 2026 Earnings Call Transcript Heritage Global Inc. (HGBL) Q2 2026 Earnings Call Transcript
- 2026-08-13 Heritage Global Inc. Reports Second Quarter 2026 Results SAN DIEGO--(BUSINESS WIRE)--Heritage Global Inc. (NASDAQ: HGBL) (“Heritage Global,” “HG” or “the Company”), an asset services company specializing in financial and industrial asset transactions, today reported financial results for the second quarter and six months ended June 30, 2026. Second Quarter and First Six Months 2026 Summary of Financial Results (unaudited): ($ in thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025.
- 2026-08-03 Heritage Global Expands Into Seller and Carryback Notes With Acquisition of Boston Note Company SAN DIEGO--(BUSINESS WIRE)--Heritage Global Inc. (NASDAQ: HGBL) (“Heritage Global,” “HG” or “the Company”), an asset services company specializing in financial and industrial asset transactions, today announced that its Financial Assets division has acquired Boston Note Company, a nationwide broker and buyer of privately held loans, notes, and mortgages, commonly known as seller notes or carry-back notes. "For 35 years Boston Note has helped the owners of seller and carry-back notes generate im.
- 2026-07-31 Heritage Global Announces Strategic Wind Down of Heritage Global Capital; Reschedules Second Quarter 2026 Earnings Conference Call to Thursday, August 13, 2026 SAN DIEGO--(BUSINESS WIRE)--Heritage Global Inc. (NASDAQ: HGBL) (“Heritage Global,” “HG” or “the Company”), an asset services company specializing in financial and industrial asset transactions, today announced that it has made the strategic decision to substantially wind down Heritage Global Capital ("HGC"), the Company''s specialty lending business. In connection with this wind down, Heritage Global expects to recognize a material non-cash charge in the second quarter of 2026 related to the wr.
- 2026-07-28 Heritage Global Partners to Conduct Online Auction of Cannabis Processing and Production Equipment from The Cannabist Company SAN DIEGO--(BUSINESS WIRE)--Heritage Global Partners (“HGP”), a subsidiary of Heritage Global Inc. (NASDAQ: HGBL) and a worldwide leader in asset advisory and auction services, announced it will conduct an online auction featuring a comprehensive offering of cannabis processing, production, packaging and facility support equipment formerly utilized by The Cannabist Company. The auction features a broad selection of late-model equipment supporting nearly every stage of cannabis production and pr.
- 2026-07-07 Heritage Global to Announce Second Quarter 2026 Results and Host Webcast on Thursday, August 6, 2026 SAN DIEGO--(BUSINESS WIRE)--Heritage Global Inc. (NASDAQ: HGBL) (“Heritage Global,” “HG” or “the Company”), an asset services company specializing in financial and industrial asset transactions, today announced that the Company will release its second quarter 2026 financial results after the market closes on Thursday, August 6, 2026. Webcast and Earnings Conference Call Management will host a webcast and conference call on Thursday, August 6, 2026, at 5:00 p.m. ET to discuss financial results f.
- 2026-06-13 Results from Incyte''s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min
- 2026-05-30 Incyte''s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min